Abstracts

Rationale: Magnetic resonance guided laser interstitial thermal therapy (LITT), also called laser ablation, is a novel, minimally invasive surgical treatment for medically intractable mesial temporal lobe epilepsy. There is a paucity of data on patterns of change in longitudinal seizure outcome (other than time to postoperative seizure recurrence) and limited to no data examining anti-seizure medication (ASM) outcomes following LITT. Thus, comprehensive long-term post-operative outcome analyses concerning Engel classification and ASM trajectories are warranted.

Methods: This study utilized retrospective data from 45 patients evaluated by the Wake Forest Baptist Health Comprehensive Epilepsy Center, spanning the past decade. Qualifying patients had medically intractable mesial temporal lobe epilepsy (MTLE) and underwent mesial temporal laser ablation following surgical evaluation. At least 12 months of postoperative follow-up was required for inclusion. Seizure outcomes and ASM data were collected from clinical visits and entered into a REDCap database. Patterns of longitudinal seizure outcomes were plotted, and participants divided into four outcome trajectory patterns: Persistent Seizure Freedom (PSF – continuous Engel I), Persistent Poor Outcome (PPO – continuous Engel III/IV), Relapse Remitting (RR – decline to Engel II), Improvement from Engel III/IV to Engel II or Better.

Results: A summary of participant demographics and clinical characteristics is shown in Table 1. Of the 45 patients, 26 were Engel I at their last visit (57.8%), 24 experienced PSF since surgery (53.3%), 8 were in the improvement group, 6 were RR and 7 had PPO. Twenty-six patients had periods of seizure freedom greater than 1 year at any point, 24 of which were PSF, 1 in the RR group, and 1 in the improvement group. Twenty-four had MRI confirmed mesial temporal sclerosis (MTS), 18 of which were Engel I at their last visit (75%). Eight of the 21 non-MTS patients were seizure free at their last visit (38%). Those in the improvement group had mean 19.7 months until said delayed benefits, and those in the RR group had mean 14.3 months until first relapse. Within PSF, 6 (25%) had successfully tapered off all ASMs by their last follow-up. Twenty-five out of 45 patients were taking lower ASM doses at last visit compared to surgery, 18 of which were in the PSF group. Further group distribution of ASM outcome is shown in Table 2. Three patients in the improvement group had medication added or dose increase prior to improvement. Two patients in the RR group had medication reduction before relapse.

Conclusions: In this long-term follow up study of mesial temporal laser ablation, while only 53% had persistent seizure freedom, nearly one-third had either initial poor outcome followed by improvement, or intermittent seizures with Engel II outcome (RR group). Medication reduction or taper was common only in the PSF group. These outcomes merit further study and are of clinical relevance for preoperative counseling.

Funding: Please list any funding that was received in support of this abstract.: Wake Forest Baptist Health Department of Neurology.